



HAL
open science

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

Annabelle Bédard, Josep M. Antó, Joao A. Fonseca, Sylvie Arnavielhe, Claus Bachert, Anna Bedbrook, Carsten Bindslev-Jensen, Sinthia Bosnic-Anticevich, Victoria Cardona, Alvaro A. Cruz, et al.

► **To cite this version:**

Annabelle Bédard, Josep M. Antó, Joao A. Fonseca, Sylvie Arnavielhe, Claus Bachert, et al.. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App. *Allergy*, 2020, 75 (7), pp.1672-1688. 10.1111/all.14204 . hal-02462027

HAL Id: hal-02462027

<https://hal.science/hal-02462027v1>

Submitted on 29 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air[®] App

Annabelle Bédard^{1,2,3} | Josep M. Antó^{1,2,3,4} | Joao A. Fonseca^{5,6} | Sylvie Arnavielhe⁷ |
Claus Bachert⁸ | Anna Bedbrook⁹ | Carsten Bindslev-Jensen¹⁰ |
Sinthia Bosnic-Anticevich¹¹ | Victoria Cardona¹² | Alvaro A. Cruz¹³ |
Wytske J. Fokkens^{14,15} | Judith Garcia-Aymerich^{1,2,3} | Peter W. Hellings^{15,16,17} |
Juan C. Ivancevich¹⁸ | Ludger Klimek¹⁹ | Piotr Kuna²⁰ | Violeta Kvedariene^{21,22} |
Désirée Larenas-Linnemann²³ | Erik Melén^{24,25} | Ricardo Monti²⁶ | Ralf Mösges^{27,28} |
Joaquim Mullol^{29,30} | Nikos G. Papadopoulos³¹ | Nhân Pham-Thi³² |
Boleslaw Samolinski³³ | Peter V. Tomazic³⁴ | Sanna Toppila-Salmi³⁵ |
Maria Teresa Ventura³⁶ | Arzu Yorgancioglu³⁷ | Jean Bousquet^{8,38,39,40,15,41,42} |
Oliver Pfaar⁴³ | Xavier Basagaña^{1,2,3} | the MASK study groupJr

¹ISGlobal, Barcelona, Spain

²Universitat Pompeu Fabra (UPF), Barcelona, Spain

³CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

⁴IMIM (Hospital del Mar Research Institute), Barcelona, Spain

⁵CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal

⁶Medida, Lda Porto, Porto, Portugal

⁷KYomed INNOV, Montpellier, France

⁸Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium

⁹MACVIA-France, Montpellier, France

¹⁰Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark

¹¹Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia

¹²Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain

¹³ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil

¹⁴Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands

¹⁵Euforea, Brussels, Belgium

¹⁶Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium

¹⁷Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

¹⁸Servicio de Alergia e Inmunología, Clínica Santa Isabel, Buenos Aires, Argentina

¹⁹Center for Rhinology and Allergology, Wiesbaden, Germany

²⁰Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland

²¹Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania

Abbreviations: AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; CSMS, combined symptom and medication score; EAACI, European Academy of Allergy and Clinical Immunology; EQ-5D, EuroQuol; ICT, information and communications technology; IER, Insufficient effort responding; IRV, Intra-individual response variability; MASK, Mobile Airway Sentinel Network; SMS, Symptom-medication score; VAS, visual analogue scale.

MASK study group members in Appendix.

- ²⁴Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden
- ²⁵Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- ²⁶Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino & Mauriziano Hospital, Torino, Italy
- ²⁷Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany
- ²⁸CRI-Clinical Research International-Ltd, Hamburg, Germany
- ²⁹Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain
- ³⁰Clinical & Experimental Respiratory Immunology, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain
- ³¹Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK
- ³²Allergy Department, Pasteur Institute, Paris, France
- ³³Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
- ³⁴Department of General ORL, H&NS, Medical University of Graz, Graz, Austria
- ³⁵Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland
- ³⁶Unit of Geriatric Immunology, University of Bari Medical School, Bari, Italy
- ³⁷Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
- ³⁸University Hospital, Montpellier, France
- ³⁹INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France
- ⁴⁰UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France
- ⁴¹Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- ⁴²Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany
- ⁴³Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität, Marburg, Germany

Correspondence

Xavier Basagaña, ISGlobal, C/ Doctor Aiguader 88, 08003 Barcelona, Spain.
Email: xavier.basagana@isglobal.org

Funding information

Macvia France

Abstract

Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently.


Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated.

Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures.

Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.

KEYWORDS

asthma, MASK, rhinitis, score, visual analogue scale



GRAPHICAL ABSTRACT

VAS work can be used as a measure of cost-effectiveness of interventions in allergic rhinitis. Strong correlations were observed between VAS work and other VAS scores, which are unlikely to be explained by a low quality of data arising from repeated VAS measures. Lower correlations were observed between VAS work and SMSs, suggesting that better SMSs need to be defined to investigate the effect of allergic rhinitis treatments.

Abbreviations: mCSMS, modified Combined Symptom Medication Score; SMSs; Symptom Medication Scores (SMSs); VAS, Visual Analogue Scale

1 | INTRODUCTION

In allergic rhinitis (AR) and asthma, a relevant outcome providing information on the cost-effectiveness of interventions is needed. EQ-5D, a validated measure of quality of life, has been used in AR¹⁻⁷ but it cannot be assessed daily.

MASK-air (Mobile Airways Sentinel Network) is an information and communication technology (ICT) system centred around the patient (Supporting information)⁸⁻¹³ and operational in 23 countries. It uses a treatment scroll list which includes all medications customized for each country as well as visual analogue scales (VASs) to assess global allergy, rhinitis, eye and asthma control. Over 30 000 users and 250 000 VAS days have been recorded. A pilot study found a highly significant correlation between VAS work and other VAS measurements (global, nose, eyes and asthma).¹⁴

Symptom-medication scores (SMSs) are also needed to investigate the effect of AR treatments, in particular allergen immunotherapy (AIT).¹⁵ The European Academy of Allergy and Clinical Immunology (EAACI) has defined the combined symptom and medication score (CSMS) for AIT trials.¹⁶

Surveys collect information but data quality is a concern: in particular, insufficient effort responding (IER), a phenomenon by which respondents try to complete the questionnaire with the shortest time without providing reliable information.¹⁷ This can result in respondents providing the same value for all questions, which will artificially increase the correlation between items.¹⁸ Several methods are used to assess data quality including the intra-individual response variability (IRV) index, a flexible way to detect IER.¹⁷

This study aimed to compare VAS work with other VAS measurements and SMSs obtained concurrently. In order to investigate data quality, we also assessed the IRV index.¹⁷

2 | METHODS

2.1 | Users

All consecutive MASK-air users from 1 June 2016 to 31 October 2018 were included with no exclusion criteria, according to methods previously described.¹⁹⁻²¹ MASK-air® was used by people who found it on the Internet, Apple store, Google Play or in any other way. Some users were clinic patients who were asked by their physicians to use the app. This was the case for the transfer of innovation project.²² However, due to anonymization of data, no specific information could be gathered, as previously described in detail.^{19,23}

2.2 | Setting

Users from 23 countries filled in the MASK-air *Allergy Diary* (Table 1).

2.3 | Ethics

The Allergy Diary is CE1. CE marking indicates conformity with health, safety and environmental protection standards for products

TABLE 1 Number of users recording visual analogue scale score using MASK-air[®] by country

Country	Number of days	Number of users	Number of days per user (median, p25-p75)	Transfer of innovation
Argentina	1522	136	2 [1-6.5]	No
Austria	5348	498	1 [1-4]	No
Australia	2080	180	2 [1-7.5]	No
Belgium	1456	168	1 [1-6]	No
Brazil	8299	1336	1 [1-4]	No
Canada	204	31	2 [1-4]	No
Czech republic	1078	51	3 [1-17]	Yes
Denmark	993	103	2 [1-6]	No
Finland	3612	360	2 [1-5]	No
France	6794	911	1 [1-3]	No ^a
Germany	14 877	895	2 [1-13]	Yes (partly)
Greece	7824	320	10 [2-28]	RCT
Italy	29 889	1562	2 [1-11]	Yes
Lithuania	20 881	572	9.5 [2-36]	Yes
Mexico	44 123	1225	15 [4-45]	Yes
Netherlands	7509	944	2 [1-5]	No
Poland	10 295	914	2 [1-6]	No
Portugal	11 310	1506	2 [1-4]	No
Spain	14 880	771	4 [1-17]	RCT
Sweden	1359	131	2 [1-7]	No
Switzerland	3955	815	1 [1-2]	No
Turkey	2595	238	2 [1-5]	No
UK	5021	522	2 [1-8]	No
Total	205 904	14 189		

Abbreviations: RCT, trial was carried out in the country.

^aThe transfer of innovation was started late and could not be considered in the study

made in the EU and meets the essential requirements of all relevant European Medical Device Directives.²⁴ The data were anonymized.

An independent Review Board approval was not required since the study is observational and users agreed to have their data analysed (terms of use).

2.4 | MASK-air[®] and outcomes

Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work—asked in this order—with several other screens in between (Figure S1). Users input their daily medications using a scroll list containing all country-specific OTC and prescribed medications for each country.

Two SMSs were used: the modified EAACI CSMS score,¹⁶ accounting for a new medication that did not exist when it was devised (Table 2), and the MASK control score for rhinitis proposed according to existing data¹³ (Table 3). Medications considered in the study are detailed in Table S1.

2.5 | Statistical methods and analyses

A non-Gaussian distribution was found for the data. Nonparametric tests and medians (and percentiles) were used. Some users reported VAS scores more than once a day, and we used the highest level.¹³

For each score, we calculated and compared: (a) the within-subject correlation with VAS work (calculated using fixed-effect models

TABLE 2 Definition of the modified EAACI CSMS

- $mCSMS = \frac{\text{Symptom Score} + \text{Medication Score}}{2}$, where symptom score is the 0-100 global VAS score, and medication score is a 0-100 score depending on the medication taken. For the latter, we used the following proposed scoring system:
 - no medication = 0 points;
 - oral non-sedative H1 antihistamines (H1A) lone = $100 \times \frac{1}{4} = 25$ points;
 - intra-nasal corticosteroids (INCS) – except Azelastine-Fluticasone Propionate combination (MPAzeFlu) - with/without H1A = $100 \times \frac{2}{4} = 50$ points;
 - MPAzeFlu = $100 \times \frac{3}{4} = 75$ points;
 - oral corticosteroids with/without INCS, with/without H1A, with/without MPAzeFlu = 100 points.

TABLE 3 Definition of the MASK rhinitis control score

<p>The MASK rhinitis control score was equal to 1 if:</p> <ol style="list-style-type: none"> 1. VAS global \geq 50/100 <p>or</p> <ol style="list-style-type: none"> 2. VAS global \geq 35 with the use of INCS-containing medication <p>or</p> <ol style="list-style-type: none"> 3. VAS global \geq 20 with the use of at least 3 medications <p>The MASK rhinitis control score was equal to 0 otherwise.</p>

using the Stata xtreg command) and (b) the variance explained in VAS work (which corresponds to the correlation measured in (a) squared). Only person-days with a reported VAS work were tested. Differences in correlations by gender, age (above *versus* below median age—ie 32 years old) and season (pollen season—ie from 15 March to the end of June, *versus* the period outside pollen season—ie from August to December) were investigated. Regarding VAS asthma, since not all users are asthmatic, a lot of nonasthmatic users will fill in a VAS asthma of 0 (no missing information is allowed) when using the app. Therefore, differences in the correlation between VAS work and VAS asthma by asthma status were investigated.

The intra-individual response variability (IRV) index was calculated, based on answers to the five VAS scores, to detect IER.¹⁷ All person-days were tested. The IRV is the standard deviation of responses across a set of consecutive item responses for an individual. It is an indicator of insufficient effort responding.

The number of days of reporting per user was examined and a Mann-Whitney *U* test was used to make comparisons in countries

where physicians were including patients using the transfer of innovation (Twinning) project²² and in countries where this was not the case. This analysis was repeated after excluding countries with low numbers of users (eg Canada and Czech Republic).

3 | RESULTS

3.1 | Users

The study included 14 189 users and 205 904 days (Table 1). Approximately 5% of users did not report their age or reported an age below 10. Users ranged in age from zero to 92 years (mean, SD: 32.1 \pm 15.3 years). There were 55.3% women and 44.7% men. 98 303 days were tested for VAS work correlations. In this group, there were 53 241 (54.2%) days without treatment (Figure 1).

3.2 | Main results

A strong correlation was observed between VAS work and other VAS (Table 4). The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work and explained less variance in VAS work.

The within-subject correlation between VAS work and VAS global did not vary by age, gender or season. For the other outcomes, the within-subject correlation with VAS work did not vary substantially between males and females (ie difference of less than 5%) or between days recorded during and outside the pollen season (ie difference of less than 4%). When we stratified by median age (ie 32 years old), the correlation varied the most between VAS work and VAS eyes (ie within-subject correlations of 0.60 for days recorded by older users and 0.52 for days recorded by younger users) and between VAS work and VAS asthma (ie within-subject correlations of 0.48 for days recorded by older users and 0.40 for days recorded by younger users).

The within-subject correlation between VAS work and VAS asthma was higher in days recorded by users who reported asthma when they started using the app, compared to days recorded by users who did not report asthma ($r = .54$ vs $.38$).

3.3 | Intra-individual response variability

Of the 205 904 person-days, there was no variability in 35 592 days (17.3%) (users respond with the same value to all five VAS). 35 373 (99.4%) of them corresponded to a value of zero (no symptoms) answered to all questions. Without counting person-days with all variables at zero, 48 086 person-days (23.4%) had an IRV \leq 3.6 (Table 5). An IRV of 3.6 implies a difference of up to 10 points (on a 0-100 point scale) in at least one of the VAS measures.


**FIGURE 1** Flow chart of the study population

TABLE 4 Within-subject correlations between VAS work and other rhinitis scores

	Number of days	Continuous scores					Binary score MASK control score
		VAS global	VAS nose	VAS eyes	VAS asthma	mCSMS	
Median, 25%-75% (continuous outcomes) or % (binary outcome)	98 303	11 [1-29]	12 [1-30]	3 [0-18]	0 [0-9]	25 [3-56]	84% controlled 16% uncontrolled
Within-subject correlation with VAS work	98 303	0.73	0.68	0.56	0.45	0.56	0.54
Variance explained in VAS work	98 303	0.53	0.46	0.32	0.20	0.31	0.29

As a *post hoc* analysis, we recalculated the correlations with VAS work and variances explained in VAS work, after excluding person-days with low intra-individual response variability (ie defined as $IRV \leq 3.6$) and similar results were obtained (Table S2).

3.4 | Number of days of reporting

The number of days of reporting per user was significantly greater in countries where a transfer of innovation was carried out than in those that did not perform this project (*P* for Mann-Whitney *U* test = .0001) (Table 1). When this analysis was repeated after excluding countries with low numbers of users (eg Canada and Czech Republic), the difference remained highly statistically significant (*P* for Mann-Whitney *U* test < .0001).

4 | DISCUSSION

The strengths of the study are the sample size and the wide distribution of users in 23 countries and 17 languages. There is one strong message and two extra messages. First, there is a high correlation between VAS work and rhinitis control assessed by VAS global or nose. Second, the strong correlations we observed between VAS work and other VAS scores are unlikely to be explained by a low quality of data arising from repeated VAS measures. Third, in comparison with VAS global, the two SMSs showed a lower correlation with VAS work and explained less variance in VAS work.

Our results are unlikely to be explained by a low quality of data arising from repeated VAS measures: (a) VAS work is the last VAS measure assessed, and it is measured after 5 screens without any VAS question, which makes it more difficult to reproduce the previous VAS (Figure S1); (b) correlations differ between outcomes; (c) over 99% of the person-days with no variation in the five VAS measures corresponded to a value of zero answered to all of them, which is plausible in days with no symptoms; (d) a very low variability in VAS measures was assessed by taking a cut-off of IRV index below 3.6. Although other cut-off values could be used, this represents a realistic maximal difference of 10 points on a 0-100 point scale of some of the VAS measures. Only 23.4% of person-days had a low variability in the response to several questions and were suspected of engaging in IER. However, this is an upper bound, as low variability in responses is actually possible in reality (ie on days in which the

patient has the same or similar degree of impairment for all questions); (e) the strong correlations found between the different scores and VAS work were not substantially reduced when person-days with low intra-individual response variability were excluded from the analyses, suggesting that they are not “artificially” driven by IER.

In order to determine the relative cost-effectiveness of new interventions, many countries propose to conduct a health economic evaluation either by adopting a healthcare perspective only or by adding a societal perspective aiming to include all relevant effects and costs.²⁵ Productivity costs are frequently omitted from economic evaluations, despite their often strong impact on cost-effectiveness outcomes, partly because of the lack of standardization regarding the methodology of estimating productivity costs.²⁶ Allergic rhinitis impairs quality of life²⁷ but never induces death. Thus, the decision analytic modelling (DAM) model may be difficult to apply.²⁸ EQ5D is impaired in severe AR whereas work productivity is often impaired in moderate AR.²⁹ Thus, VAS work may be a more sensitive surrogate end point to assess the economic evaluation of an intervention in AR. Moreover, a *daily* assessment of work productivity can be carried out with VAS. Using the novel feature of MASK, the integration of pollen season and air quality the same day as VAS work will provide a very sensitive outcome on health economics for clinical trials. In clinical practice, VAS global may be more relevant. To our knowledge, limitations of real-world data using an app are the same for all VAS measurements. VAS work validation was not done since this criterion was not included in the first version of the app.

In comparison with VAS global, the two SMSs showed a lower correlation with VAS work, and explained less variance in VAS work. This is probably because we used simple methods to assess SMSs and more sophisticated analyses are needed. In particular, it seems that adding the same coefficient to a symptom score or a VAS level may not be optimal. From the real-world evidence from MASK,^{13,21} it appears that (a) medications may have a different efficacy depending on rhinitis control level: higher impact for a lower VAS level and lower impact for a higher VAS level and (b) co-medication may be considered. New SMS are therefore needed.

One of the major problems with apps is the low adherence to their use. Achieving sufficient mHealth App engagement and user retention rates is a difficult task. In MASK, over 50% of the users use the app only once. Differences in the duration of reporting were found. It is clear that in countries where many patients have been enrolled by physicians during a transfer of innovation, the duration of reporting is longer than in countries where this protocol was not

TABLE 5 Intra-individual response variability (ie based on answers to the five VAS scores)

IRV	Number of person-days	Example of VAS values in a representative patient
0.44	2422	One of the VAS measures differs in 1 unit (ie on a 0-100 point scale) from the rest. For example, providing the following values for the five VAS measures: (0,0,1,0,0)
0.5	2622	One of the VAS measures differs in 1 unit from the rest (among person-days that have one missing value) For example, providing the following values for the five VAS measures: (0,0,1,0, missing)
0.548	1003	Two VAS measures differ in 1 unit from the rest. For example, providing the following values for the five VAS measures: (8,7,8,8,7)
1	1330	Variations of 3 units among the VAS measures. For example, providing the following values for the five VAS measures: (42,41,42,40,40)
1.5	1431	One of the VAS measures differs in 3 units from the rest (among person-days that have one missing value). For example, providing the following values for the five VAS measures: (22,22,19,22, missing)
2	690	Variations of 5 units among the VAS measures. For example, providing the following values for the five VAS measures: (26,24,27,22,26)
3.6	44	Variations of up to 10 units among the VAS measures. For example, providing the following values for the five VAS measures: (56,52,50,51,46)
Total ≤ 3.6	48 086 (23.4%) ^a	

^aNot counting person-days with all 0 values.

used. This information should be carefully considered to increase adherence to MASK use.

5 | GENERALIZABILITY

The data obtained were retrieved from 23 countries. Although there was no specific study in the different countries, the results appear generalizable.

6 | CONCLUSION

This study suggests that VAS work can be used as a surrogate end point for the assessment of health economics in rhinitis and that symptom-medication scores tested with real-world data need to be improved.

CONFLICTS OF INTEREST

Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work. Dr Bosnic-Anticevich reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan, outside the submitted work. Dr Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI,

Thermofisher, Stallergenes, outside the submitted work. Dr Fonseca being a partner in a company developing mobile technologies for monitoring airways diseases. Dr Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, Allergopharma, Stallergenes, outside the submitted work. Dr Ivancevich reports personal fees from Faes Farma, Eurofarma Argentina, other from Sanofi, Laboratorios Casasco, personal fees from, outside the submitted work. Dr Kuna reports personal fees from Adamed, AstraZeneca, Boehringer Ingelheim, Hal, Chiesi, Novartis, Berlin Chemie Menarini, outside the submitted work. Dr Kvedariene reports personal fees from GSK, non-financial support from StallergenGreer, Mylan, AstraZeneca, Dimuna, Noramed, outside the submitted work. Dr Larenas Linnemann reports personal fees from Armstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi, outside the submitted work. Dr MULLOL reports personal fees from SANOFI-Genzyme-Regeneron, ALK-Abelló A/S, Menarini Group, MSD, GlaxoSmithKline, Novartis, GENENTECH - Roche_Novartis, grants and personal fees from UCB Pharma, MYLAN-MEDA Pharma, URIACH Group, outside the submitted work. Dr Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer

Ingelheim, grants from Gerolymatos International SA, Capricare, outside the submitted work. Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work. Dr Pfaar reports personal fees from MEDA Pharma/MYLAN, ASIT Biotech Tools SA Laboratorios LETI/LETI Pharma, Anergis S.A, Mobile Chamber Experts (a GA²LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, Nuvo, Circassia, from, Glaxo Smith Kline, outside the submitted work.

AUTHOR CONTRIBUTIONS

A Bédard, JM Anto, JA Fonseca, X Basagana and J Bousquet conceived the study and drafted the manuscript. A Bédard and X Basagana conducted the statistical analyses. O Pfaar and J Bousquet designed the symptom-medications scores used in the analyses. All authors reviewed the study design and the manuscript and have approved the final version of the manuscript".

REFERENCES

- Poole CD, Bannister CA, Andreasen JN, Andersen JS, Currie CJ. Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. *Health Qual Life Outcomes*. 2014;12:99.
- Soler R, de la Hoz B, Badia X, et al. Validation of the Spanish version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). *Rev Clin Esp*. 2004;204(3):131-138.
- Hoehle LP, Speth MM, Phillips KM, et al. Association between symptoms of allergic rhinitis with decreased general health-related quality of life. *Am J Rhinol Allergy*. 2017;31(4):235-239.
- Hwang TY, Kim SK, Kim SH, Kim M. A cross sectional survey on health-related quality of life among parents of children with allergic symptoms using the EQ-5D-5L. *J Asthma*. 2019;56(11):1239-1245.
- Bousquet J, Arnavielhe S, Bedbrook A, et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: the MASK study. *Allergy*. 2018;73(2):505-510.
- Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a novel intranasal formulation of Azelastine hydrochloride and fluticasone propionate, delivered in a single spray, for the treatment of seasonal allergic rhinitis: results from Russia. *Int Arch Allergy Immunol*. 2019;178(3):255-263.
- Speth MM, Hoehle LP, Phillips KM, Caradonna DS, Gray ST, Sedaghat AR. Treatment history and association between allergic rhinitis symptoms and quality of life. *Ir J Med Sci*. 2019;188(2):703-710.
- Bousquet J, Anto JM, Annesi-Maesano I, et al. POLLAR: impact of air POLLution on asthma and rhinitis; a european institute of innovation and technology health (EIT Health) project. *Clin Transl Allergy*. 2018;8:36.
- Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. *Clin Transl Allergy*. 2018;8:45.
- Bourret R, Bousquet J, Mercier J, et al. MASK rhinitis, a single tool for integrated care pathways in allergic rhinitis. *World Hosp Health Serv*. 2015;51(3):36-39.
- Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. *Allergy*. 2015;70(11):1372-1392.
- Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin Transl Allergy*. 2016;6:47.
- Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights on control and treatment of allergic rhinitis. The MASK study. *J Allergy Clin Immunol*. 2019;144(1):135-143
- Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. *Allergy*. 2017;72(10):1475-1484.
- Godicke V, Hundt F. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. *Allergy*. 2010;65(12):1499-1505.
- Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. *Allergy*. 2014;69(7):854-867.
- Dunn A, Heggstad E, Shanock L, Theilgard N. Intra-individual response variability as an indicator of insufficient effort responding: comparison to other indicators and relationships with individual differences. *J Business Psychol*. 2018;33(1):105-121.
- Huang JL, Liu M, Bowling NA. Insufficient effort responding: examining an insidious confound in survey data. *J Appl Psychol*. 2015;100(3):828-845.
- Bousquet J, Caimmi DP, Bedbrook A, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. *Allergy*. 2017;72(6):857-865.
- Bousquet J, Devillier P, Anto JM, et al. Daily allergic multimorbidity in rhinitis using mobile technology: a novel concept of the MASK study. *Allergy*. 2018;73(8):1622-1631.
- Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. *Allergy*. 2018;73(9):1763-1774.
- Bousquet J, Agache I, Aliberti MR, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). *Allergy*. 2018;73(1):77-92.
- Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. *Allergy*. 2017;72(10):1475-1484
- Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. 1993L0042 – EN – 11.10.2007 – 005.001 – 1. <https://>

25. Krol M, Papenburg J, Tan SS, Brouwer W, Hakkaart L. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. *Eur J Health Econ.* 2016;17(4):391-402.
26. Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. *Pharmacoeconomics.* 2014;32(4):335-344.
27. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. *Am J Respir Crit Care Med.* 2000;162(4 Pt 1):1391-1396.
28. Briggs A, Claxton K, Sculpher M. *Decision Modelling for Health Economic Evaluation.* Oxford, UK: Oxford University Press; 2006.
29. Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of rhinitis on work productivity. A systematic review. *J Allergy Clin Immunol Pract.* 2018;6(4):1274-1286.

APPENDIX

MASK STUDY GROUP

J Bousquet¹⁻³, PW Hellings⁴, W Aberer⁵, I Agache⁶, CA Akdis⁷, M Akdis⁷, MR Aliberti⁸, R Almeida⁹, F Amat¹⁰, R Angles¹¹, I Annesi-Maesano¹², IJ Ansotegui¹³, JM Anto¹⁴⁻¹⁶⁻¹⁷, S Arnavielle¹⁸, E Asayag¹⁹, A Asaranoj²⁰, H Arshad²¹, F Avolio²², E Bacci²³, C Bachert²⁴, I Baiardini²⁵, C Barbara²⁶, M Barbagallo²⁷, I Baroni²⁸, BA Barreto²⁹, X Basagana¹⁴⁻¹⁶⁻¹⁷, ED Bateman³⁰, M Bedolla-Barajas³¹, A Bedbrook², M Bewick³², B Beghé³³, EH Bel³⁴, KC Bergmann³⁵, KS Bennoor³⁶, M Benson³⁷, L Bertorello²³, AZ Białoszewski³⁸, T Bieber³⁹, S Bialek⁴⁰, C Bindslev-Jensen⁴¹, L Bjermer⁴², H Blain^{43,44}, F Blasi⁴⁵, A Blua⁴⁶, M Bochenska Marciniak⁴⁷, I Bogus-Buczynska⁴⁷, AL Boner⁴⁸, M Bonini⁴⁹, S Bonini⁵⁰, CS Bosnic-Anticevich⁵¹, I Bosse⁵², J Bouchard⁵³, LP Boulet⁵⁴, R Bourret⁵⁵, PJ Bousquet¹², F Braidó²⁵, V Briedis⁵⁶, CE Brightling⁵⁷, J Brozek⁵⁸, C Bucca⁵⁹, R Buhl⁶⁰, R Buonaiuto⁶¹, C Panaitescu⁶², MT Burguete Cabañas⁶³, E Burte³, A Bush⁶⁴, F Caballero-Fonseca⁶⁵, D Caillaud⁶⁷, D Caimmi⁶⁸, MA Calderon⁶⁹, PAM Camargos⁷⁰, T Camuzat⁷¹, G Canfora⁷², GW Canonica²⁵, V Cardona⁷³, KH Carlsen⁷⁴, P Carreiro-Martins⁷⁵, AM Carriazo⁷⁶, W Carr⁷⁷, C Cartier⁷⁸, T Casale⁷⁹, G Castellano⁸⁰, L Cecchi⁸¹, AM Cepeda⁸², NH Chavannes⁸³, Y Chen⁸⁴, R Chiron⁶⁸, T Chivato⁸⁵, E Chkhartishvili⁸⁶, AG Chuchalin⁸⁷, KF Chung⁸⁸, MM Ciaravolo⁸⁹, A Ciceran⁹⁰, C Cingi⁹¹, G Ciprandi⁹², AC Carvalho Coelho⁹³, L Colas⁹⁴, E Colgan⁹⁵, J Coll⁹⁶, D Conforti⁹⁷, J Constantinidis³⁸³, J Correia de Sousa⁹⁸, RM Cortés-Grimaldo⁹⁹, F Corti¹⁰⁰, E Costa¹⁰¹, MC Costa-Dominguez¹⁰², AL Courbis¹⁰³, L Cox¹⁰⁴, M Crescenzo¹⁰⁵, AA Cruz¹⁰⁶, A Custovic¹⁰⁷, W Czarlewski¹⁰⁸, SE Dahlen¹⁰⁹, G D'Amato²⁷⁹, C Dario¹¹⁰, J da Silva¹¹¹, Y Dauvilliers¹¹², U Darsow¹¹³, F De Blay¹¹⁴, G De Carlo¹⁵, T Dedeu¹¹⁶, M de Fátima Emerson¹¹⁷, G De Feo¹¹⁸, G De Vries¹¹⁹, B De Martino¹²⁰, NP Motta Rubini¹²¹, D Deleanu¹²², JA Denburg¹²³, P Devillier¹²⁴, S Di Capua Ercolano¹²⁵, N Di Carluccio⁶⁶, A Didier¹²⁶, D Dokic¹²⁷, MG Dominguez-Silva¹²⁸, H Dougoui¹²⁹, G Dray¹⁰³, R Dubakienė¹³⁰, SR Durham¹³¹, G Du Toit¹³², MS Dykewicz¹³³, Y El-Gamal¹³⁴, P Eklund¹³⁵, E Eller⁴¹⁻³⁸⁴, R Emuzyte¹³⁶, J Farrell⁹⁵, A Farsi⁸¹, J Ferreira de Mello Jr¹³⁷, J Ferrero¹³⁸, A Fink-Wagner¹³⁹, A Fiocchi¹⁴⁰, WJ Fokkens¹⁴¹, JA Fonseca¹⁴², JF Fontaine¹⁴³, S Forti⁹⁷, JM Fuentes-Perez¹⁴⁴, JL Gálvez-Romero¹⁴⁵, A Gamkrelidze¹⁴⁶, J Garcia-Aymerich^{14,16,17}, CY García-Cobas¹⁴⁷, MH Garcia-Cruz¹⁴⁸, B

Gemicioğlu¹⁴⁹, S Genova¹⁵⁰, G Christoff¹⁵¹, JE Gereda¹⁵², R Gerth van Wijk¹⁵³, RM Gomez¹⁵⁴, J Gómez-Vera¹⁵⁵, S González Diaz¹⁵⁶, M Gotua¹⁵⁷, I Grisle¹⁵⁸, M Guidacci¹⁵⁹, NA Guldemand¹⁶⁰, Z Gutter¹⁶¹, MA Guzmán¹⁶², T Haahtela¹⁶³, J Hajjam¹⁶⁴, L Hernández¹⁶⁵, JO'B Hourihane¹⁶⁶, YR Huerta-Villalobos¹⁶⁷, M Humbert¹⁶⁸, G Iaccarino¹⁶⁹, M Illario¹⁷⁰, Z Ispayeva³⁸⁰, JC Ivancevich¹⁷¹, EJ Jares¹⁷², E Jassem¹⁷³, SL Johnston¹⁷⁴, G Joos¹⁷⁵, KS Jung¹⁷⁶, J Just¹⁰, M Jutel¹⁷⁷, I Kaidashev¹⁷⁸, O Kalayci¹⁷⁹, AF Kalyoncu¹⁸⁰, J Karjalainen¹⁸¹, P Kardas¹⁸², T Keil¹⁸³⁻¹⁸⁸⁻³⁸⁵, PK Keith¹⁸⁴, M Khaitov¹⁸⁵, N Khaltayev¹⁸⁶, J Kleine-Tebbe¹⁸⁷, L Klimek¹⁸⁸, ML Kowalski¹⁸⁹, M Kuitunen¹⁹⁰, I Kull¹⁹¹, P Kuna⁴⁷, M Kupczyk⁴⁷, V Kvedariene¹⁹², E Krzych-Fałta¹⁹³, P Lacwik⁴⁷, D Larenas-Linnemann¹⁹⁴, D Laune¹⁸, D Lauri¹⁹⁵, J Lavrut¹⁹⁶, LTT Le¹⁹⁷, M Lessa¹⁹⁸, G Levato¹⁹⁹, J Li²⁰⁰, P Lieberman²⁰¹, A Lipiec¹⁹³, B Lipworth²⁰², KC Lodrup Carlsen²⁰³, R Louis²⁰⁴, O Lourenço²⁰⁵, JA Luna-Pech²⁰⁶, A Magnan⁹⁴, B Mahboub²⁰⁷, D Maier²⁰⁸, A Mair²⁰⁹, I Majer²¹⁰, J Malva²¹¹, E Mandajieva²¹², P Manning²¹³, E De Manuel Keenoy²¹⁴, GD Marshall²¹⁵, MR Masjedi²¹⁶, JF Maspero²¹⁷, E Mathieu-Dupas¹⁸, JJ Matta Campos²¹⁸, AL Matos²¹⁹, M Maurer²²⁰, S Mavale-Manuel²²¹, O Mayora⁹⁷, C Meco³⁸², MA Medina-Avalos²²², E Melén²²³, E Melo-Gomes²⁶, EO Meltzer²²⁴, E Menditto²²⁵, J Mercier²²⁶, N Miculinic²²⁷, F Mihaltan²²⁸, B Milenkovic²²⁹, G Moda²³⁰, MD Mogica-Martinez²³¹, Y Mohammad²³², I Momas^{233,234}, S Montefort²³⁵, R Monti²³⁶, D Mora Bogado²³⁷, M Morais-Almeida²³⁸, FF Morato-Castro²³⁹, R Mösges²⁴⁰, A Mota-Pinto²⁴¹, P Moura Santo²⁴², J Mullol²⁴³, L Münter²⁴⁴, A Muraro²⁴⁵, R Murray²⁴⁶, R Naclerio²⁴⁷, R Nadif³, M Nalin²⁸, L Napoli²⁴⁸, L Namazova-Baranova²⁴⁹, H Neffen²⁵⁰, V Niedeberger²⁵¹, K Nekam²⁵², A Neou²⁵³, A Nieto²⁵⁴, L Nogueira-Silva²⁵⁵, M Nogues^{2,256}, E Novellino²⁵⁷, TD Nyembue²⁵⁸, RE O'Hehir²⁵⁹, C Odzhakova²⁶⁰, K Ohta²⁶¹, Y Okamoto²⁶², K Okubo²⁶³, GL Onorato², M Ortega Cisneros²⁶⁴, S Ouedraogo²⁶⁵, I Pali-Schöll²⁶⁶, S Palkonen¹¹⁵, P Panzner²⁶⁷, NG Papadopoulos²⁶⁸, HS Park²⁶⁹, A Papi²⁷⁰, G Passalacqua²⁷¹, E Paulino²⁷², R Pawankar²⁷³, S Pedersen²⁷⁴, JL Pépin²⁷⁵, AM Pereira²⁷⁶, M Persico²⁷⁷, O Pfaar²⁷⁸, J Phillips²⁸⁰, R Picard²⁸¹, B Pigearias²⁸², I Pin²⁸³, C Pitsios²⁸⁴, D Plavec²⁸⁵, W Pohl²⁸⁶, TA Popov²⁸⁷, F Portejoie², P Potter²⁸⁸, AC Pozzi²⁸⁹, D Price²⁹⁰, EP Prokopakis²⁹¹, R Puy²⁵⁹, B Pugin²⁹², RE Pulido Ross²⁹³, M Przemicka⁴⁷, KF Rabe²⁹⁴, F Raciborski¹⁹³, R Rajabian-Soderlund²⁹⁵, S Reitsma¹⁴¹,

I Ribeirinho²⁹⁶, J Rimmer²⁹⁷, D Rivero-Yeverino²⁹⁸, JA Rizzo²⁹⁹, MC Rizzo³⁰⁰, C Robalo-Cordeiro³⁰¹, F Rodenas³⁰², X Rodo³⁸¹, M Rodriguez Gonzalez³⁰³, L Rodriguez-Mañas³⁰⁴, C Rolland³⁰⁵, S Rodrigues Valle³⁰⁶, M Roman Rodriguez³⁰⁷, A Romano³⁰⁸, E Rodriguez-Zagal³⁰⁹, G Rolla³¹⁰, RE Roller-Wirnsberger³¹¹, M Romano²⁸, J Rosado-Pinto³¹², N Rosario³¹³, M Rottem³¹⁴, D Ryan³¹⁵, H Sagara³¹⁶, J Salimäki³¹⁷, B Samolinski¹⁹³, M Sanchez-Borges³¹⁸, J Sastre-Dominguez³¹⁹, GK Scadding³²⁰, HJ Schunemann⁵⁸, N Scichilone³²¹, P Schmid-Grendelmeier³²², F Sarquis Serpa³²³, S Shamai²⁴⁰, A Sheikh³²⁴, M Sierra⁹⁶, FER Simons³²⁵, V Siroux³²⁶, JC Sisul³²⁷, I Skrindo³⁷⁸, D Solé³²⁸, D Somekh³²⁹, M Sondermann³³⁰, T Sooronbaev³³¹, M Sova³³², M Sorensen³³³, M Sorlini³³⁴, O Spranger¹³⁹, C Stellato¹¹⁸, R Stelmach³³⁵, R Stukas³³⁶, J Sunyer¹⁴⁻¹⁷, J Strozek¹⁹³, A Szylling¹⁹³, JN Tebyriča³³⁷, M Thibaudon³³⁸, T To³³⁹, A Todo-Bom³⁴⁰, PV Tomazic³⁴¹, S Toppila-Salmi¹⁶³, U Trama³⁴², M Triggiani¹¹⁸, C Suppli Ulrik³⁴³, M Urrutia-Pereira³⁴⁴, R Valenta³⁴⁵, A Valero³⁴⁶, A Valiulis³⁴⁷, E Valovirta³⁴⁸, M van Eerd¹¹⁹, E van Ganse³⁴⁹, M van Hage³⁵⁰, O Vandenplas³⁵¹, MT Ventura³⁵², G Vezzani³⁵³, T Vasankari³⁵⁴, A Vatrella¹¹⁸, MT Verissimo²¹¹, F Viart⁷⁸, G Viegi³⁵⁵, D Vicheva³⁵⁶, T Vontetsianos³⁵⁷, M Wagenmann³⁵⁸, S Walker³⁵⁹, D Wallace³⁶⁰, DY Wang³⁶¹, S Wasserman³⁶², T Werfel³⁶³, M Westman³⁶⁴, M Wickman¹⁹¹, DM Williams³⁶⁵, S Williams³⁶⁶, N Wilson³⁷⁹, J Wright³⁶⁷, P Wroczynski⁴⁰, P Yakovliev³⁶⁸, BP Yawn³⁶⁹, PK Yiallourous³⁷⁰, A Yorgancioglu³⁷¹, OM Yusuf³⁷², HJ Zar³⁷³, L Zhang³⁷⁴, N Zhong²⁰⁰, ME Zernotti³⁷⁵, I Zhanat³⁸⁰, M Zidarn³⁷⁶, T Zuberbier³⁵, C Zubrinich²⁵⁹, A Zurkühlen³⁷⁷

¹University Hospital, Montpellier, France.

²MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France.

³VIMA. INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France and Euforea, Brussels, Belgium and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.

⁴Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

⁵Department of Dermatology, Medical University of Graz, Graz, Austria.

⁶Transylvania University Brasov, Brasov, Romania.

⁷Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.

⁸Project Manager, Chairman of the Council of Municipality of Salerno, Italy.

⁹Center for Health Technology and Services Research- CINTESIS, Faculdade de Medicina, Universidade do Porto; and Medida, Lda Porto, Portugal.

¹⁰Allergology department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP); Sorbonne Université, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre

Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France.

¹¹Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain.

¹²Equipe EPAR-IPLESP, Sorbonne Université, Paris, France.

¹³Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain.

¹⁴ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.

¹⁵IMIM (Hospital del Mar Research Institute), Barcelona, Spain.

¹⁶CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

¹⁷Universitat Pompeu Fabra (UPF), Barcelona, Spain.

¹⁸KYomed INNOV, Montpellier, France.

¹⁹Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina.

²⁰Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, and Astrid Lindgren Children's Hospital, Department of Pediatric Pulmonology and Allergy, Karolinska University Hospital, Stockholm, Sweden.

²¹David Hide Asthma and Allergy Research Centre, Isle of Wight, United Kingdom.

²²Regionie Puglia, Bari, Italy.

²³Regione Liguria, Genoa, Italy.

²⁴Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.

²⁵University of Genoa, Department of Internal Medicine (DiMI) and IRCCS Ospedale Policlinico San Martino, Genova, Italy.

²⁶PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal.

²⁷Director of the Geriatric Unit, Department of Internal Medicine (DIBIMIS), University of Palermo, Italy.

²⁸Telbios SRL, Milan, Italy.

²⁹Universidade do Estado do Pará, Belem, Brazil.

³⁰Department of Medicine, University of Cape Town, Cape Town, South Africa.

³¹Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalajara, Mexico.

³²iQ4U Consultants Ltd, London, UK.

³³Section of Respiratory Disease, Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.

³⁴Department of Respiratory Medicine, Academic Medical Center (AMC), University of Amsterdam, The Netherlands.

³⁵Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Global Allergy and Asthma European Network (GA²LEN), Berlin, Germany.

³⁶Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.

- ³⁷Centre for Individualized Medicine, Department of Pediatrics, Faculty of Medicine, Linköping, Sweden.
- ³⁸Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland.
- ³⁹Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany
- ⁴⁰Dept of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland.
- ⁴¹Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.
- ⁴²Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden.
- ⁴³Department of Geriatrics, Montpellier University Hospital, Montpellier, France.
- ⁴⁴EA 2991, Euromov, University Montpellier, France.
- ⁴⁵Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
- ⁴⁶Argentine Association of Respiratory Medicine, Buenos Aires, Argentina.
- ⁴⁷Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland.
- ⁴⁸Pediatric Department, University of Verona Hospital, Verona, Italy.
- ⁴⁹UOC Pneumologia, Istituto di Medicina Interna, F. Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, and National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, UK.
- ⁵⁰Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.
- ⁵¹Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.
- ⁵²Allergist, La Rochelle, France.
- ⁵³Associate professor of Clinical Medicine, Laval's University, Quebec city, Canada.
- ⁵⁴Quebec Heart and Lung Institute, Laval University, Québec City, Quebec, Canada.
- ⁵⁵Centre Hospitalier Valenciennes, France.
- ⁵⁶Head of Department of Clinical Pharmacy of Lithuanian University of Health Sciences, Kaunas, Lithuania.
- ⁵⁷Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
- ⁵⁸Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, McMaster University, Hamilton, ON, Canada.
- ⁵⁹Chief of the University Pneumology Unit- AOU Molinette, Hospital City of Health and Science of Torino, Italy.
- ⁶⁰Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany.
- ⁶¹Pharmacist, Municipality Pharmacy, Sarno, Italy.
- ⁶²University of Medicine and Pharmacy Victor Babes, Timisoara, Romania.
- ⁶³Instituto de Pediatria, Hospital Zambrano Hellion Tec de Monterrey, Monterrey, Mexico.
- ⁶⁴Imperial College and Royal Brompton Hospital, London, UK.
- ⁶⁵Centro Medico Docente La Trinidad, Caracas, Venezuela.
- ⁶⁶Regional Director Assofarm Campania and Vice President of the Board of Directors of Cofaser, Salerno, Italy
- ⁶⁷Service de pneumologie, CHU et université d'Auvergne, Clermont-Ferrand, France.
- ⁶⁸Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.
- ⁶⁹Imperial College London - National Heart and Lung Institute, London, UK.
- ⁷⁰Federal University of Minas Gerais, Medical School, Department of Pediatrics, Belo Horizonte, Brazil
- ⁷¹Assistant Director General, Montpellier, Région Occitanie, France.
- ⁷²Mayor of Sarno and President of Salerno Province, Director, Anesthesiology Service, Sarno "Martiri del Villa Malta" Hospital, Italy.
- ⁷³Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Spanish Research Network, Barcelona, Spain.
- ⁷⁴Department of Paediatrics, Oslo University Hospital and University of Oslo, Oslo, Norway.
- ⁷⁵Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, EPE, Lisbon, and Nova Medical School, CEDOC, Integrated Pathophysiological Mechanisms Research Group, Lisbon, Portugal.
- ⁷⁶Regional Ministry of Health of Andalusia, Seville, Spain.
- ⁷⁷Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA.
- ⁷⁸ASA - Advanced Solutions Accelerator, Clapiers, France.
- ⁷⁹Division of Allergy/Immunology, University of South Florida, Tampa, Fla, USA.
- ⁸⁰Celentano pharmacy, Massa Lubrense, Italy.
- ⁸¹SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy.
- ⁸²Allergy and Immunology Laboratory, Metropolitan University Hospital, Branquilla, Columbia.
- ⁸³Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
- ⁸⁴Capital Institute of Pediatrics, Chaoyang district, Beijing, China.
- ⁸⁵School of Medicine, University CEU San Pablo, Madrid, Spain.
- ⁸⁶David Tvildiani Medical University - AIETI Highest Medical School, David Tashvili Medical Center Tbilisi, Georgia.
- ⁸⁷Pulmonology Research Institute FMBA, Moscow, Russia and GARD Executive Committee, Moscow, Russia.
- ⁸⁸National Heart & Lung Institute, Imperial College, London, UK.
- ⁸⁹Specialist social worker, Sorrento, Italy.
- ⁹⁰Argentine Federation of Otorhinolaryngology Societies, Buenos Aires, Argentina.

- ⁹¹Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey.
- ⁹²Medicine Department, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy.
- ⁹³Universidade Federal da Bahia, Escola de Enfermagem, Brazil.
- ⁹⁴Plateforme Transversale d'Allergologie, Institut du Thorax, CHU de Nantes, Nantes, France.
- ⁹⁵LANUA International Healthcare Consultancy, Northern Ireland, UK.
- ⁹⁶Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain.
- ⁹⁷Innovation and Research Office, Department of Health and Social Solidarity, Autonomous Province of Trento, Italy.
- ⁹⁸Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
- ⁹⁹Servicio de Allergología, Hospital Angeles del Carmen, Guadalajara, Mexico.
- ¹⁰⁰FIMMG (Federazione Italiana Medici di Medicina Generale), Milan, Italy.
- ¹⁰¹UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal.
- ¹⁰²Allergologo, Mexico City, Mexico.
- ¹⁰³IMT Mines Alès, Université Montpellier, Alès, France.
- ¹⁰⁴Department of Medicine, Nova Southeastern University, Davie, University of Miami Dept of Medicine, Miami, Florida, USA.
- ¹⁰⁵Regional Director Assofarm Campania and Vice President of the Board of Directors of Cofaser, Salerno, Italy.
- ¹⁰⁶ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and GARD/WHO Executive Committee and Federal University of Bahia, Brazil.
- ¹⁰⁷Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, UK.
- ¹⁰⁸Medical Consulting Czarlewski, Levallois, France.
- ¹⁰⁹The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- ¹¹⁰Azienda Provinciale per i Servizi Sanitari di Trento (APSS-Trento), Italy.
- ¹¹¹Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianópolis, Santa Catarina, Brazil.
- ¹¹²Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, France.
- ¹¹³Department of Dermatology and Allergy, Technische Universität München, Munich, Germany; ZAUM-Center for Allergy and Environment, Helmholtz Center Munich, Technische Universität München, Munich, Germany.
- ¹¹⁴Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France.
- ¹¹⁵EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium
- ¹¹⁶International Foundation for Integrated Care (IFIC), Wolfson College, Oxford, UK
- ¹¹⁷Policlínica Geral do Rio de Janeiro, Rio de Janeiro - Brazil
- ¹¹⁸Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
- ¹¹⁹Peercode BV, Geldermalsen, The Netherlands.
- ¹²⁰Social workers coordinator, Sorrento, Italy.
- ¹²¹Federal University of the State of Rio de Janeiro, School of Medicine and Surgery, Rio de Janeiro, Brazil
- ¹²²Allergology and Immunology Discipline, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- ¹²³Department of Medicine, Division of Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.
- ¹²⁴Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes, Université Versailles Saint-Quentin, Université Paris Saclay, France.
- ¹²⁵Farmacie Dei Golfi Group, Massa Lubrense, Italy.
- ¹²⁶Rangueil-Larrey Hospital, Respiratory Diseases Department, Toulouse, France.
- ¹²⁷University Clinic of Pulmology and Allergy, Medical Faculty Skopje, Republic of Macedonia.
- ¹²⁸Allergologist, Mexico City, Mexico.
- ¹²⁹Service de Pneumo-Allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algiers, Algeria.
- ¹³⁰Clinic of infectious, chest diseases, dermatology and allergology, Vilnius University, Vilnius, Lithuania.
- ¹³¹Allergy and Clinical Immunology National Heart and Lung Institute, Imperial College London, UK.
- ¹³²Guy's and St Thomas' NHS Trust, Kings College London, UK.
- ¹³³Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
- ¹³⁴Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.
- ¹³⁵Department of Computing Science, Umeå University, Sweden and Four Computing Oy, Finland.
- ¹³⁶Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
- ¹³⁷University of São Paulo Medical School, Sao Paulo, Brazil
- ¹³⁸Andalusian Agency for Healthcare Quality, Seville, Spain.
- ¹³⁹Global Allergy and Asthma Platform GAAPP, Vienna, Austria.
- ¹⁴⁰Division of Allergy, Department of Pediatric Medicine - The Bambino Gesù Children's Research Hospital Holy see, Rome, Italy.
- ¹⁴¹Department of Otorhinolaryngology, Academic Medical Centers, Amsterdam, the Netherlands, and EUFOREA, Brussels, Belgium.
- ¹⁴²CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal and MEDIDA, Lda, Porto, Portugal.
- ¹⁴³Allergist, Reims, France.
- ¹⁴⁴Hospital General Regional 1 "Dr Carlos Mc Gregor Sanchez Navarro" IMSS, Mexico City, Mexico.

- ¹⁴⁵Regional hospital of ISSSTE, Puebla, Mexico.
- ¹⁴⁶National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.
- ¹⁴⁷Allergologo, Guadalajara, Mexico.
- ¹⁴⁸Allergy Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico.
- ¹⁴⁹Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
- ¹⁵⁰Allergology unit, UHATEM "NIPirogov", Sofia, Bulgaria.
- ¹⁵¹Medical University, Faculty of Public Health, Sofia, Bulgaria.
- ¹⁵²Allergy and Immunology Division, Clinica Ricardo Palma, Lima, Peru.
- ¹⁵³Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam, The Netherlands.
- ¹⁵⁴Allergy & Asthma Unit, Hospital San Bernardo Salta, Argentina.
- ¹⁵⁵Allergy Clinic, Hospital Regional del ISSSTE 'Lic. López Mateos', Mexico City, Mexico.
- ¹⁵⁶Head and Professor, Centro Regional de Excelencia CONACYT y WAO en Alergia, Asma e Inmunología, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey NL, Mexico.
- ¹⁵⁷Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia.
- ¹⁵⁸Latvian Association of Allergists, Center of Tuberculosis and Lung Diseases, Riga, Latvia.
- ¹⁵⁹Federal District Base Hospital Institute, Brasília, Brazil.
- ¹⁶⁰Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, The Netherlands.
- ¹⁶¹University Hospital Olomouc – National eHealth Centre, Czech Republic.
- ¹⁶²Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile.
- ¹⁶³Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
- ¹⁶⁴Centich (Centre d'Expertise National des Technologies de l'Information et de la Communication pour l'autonomie), Groupe VyV, Conseil régional des Pays de la Loire, Centre d'expertise Partenariat Européen d'Innovation pour un vieillissement actif et en bonne santé, Nantes, France.
- ¹⁶⁵Autonomous University of Baja California, Ensenada, Baja California, Mexico.
- ¹⁶⁶Department of Paediatrics and Child Health, University College Cork, Cork, Ireland.
- ¹⁶⁷Hospital General Regional 1 "Dr Carlos MacGregor Sánchez Navarro" IMSS, Mexico City, Mexico.
- ¹⁶⁸Université Paris-Sud; Service de Pneumologie, Hôpital Bicêtre; Inserm UMR_S999, Le Kremlin Bicêtre, France.
- ¹⁶⁹Dipartimento di medicina, chirurgia e odontoiatria, università di Salerno, Italy.
- ¹⁷⁰Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET) Naples, Italy.
- ¹⁷¹Servicio de Alergia e Inmunología, Clinica Santa Isabel, Buenos Aires, Argentina.
- ¹⁷²President, Libra Foundation, Buenos Aires, Argentina.
- ¹⁷³Medical University of Gdańsk, Department of Allergology, Gdansk, Poland.
- ¹⁷⁴Airway Disease Infection Section, National Heart and Lung Institute, Imperial College; MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
- ¹⁷⁵Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
- ¹⁷⁶Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea.
- ¹⁷⁷Department of Clinical Immunology, Wrocław Medical University, Poland.
- ¹⁷⁸Ukrainina Medical Stomatological Academy, Poltava, Ukraine.
- ¹⁷⁹Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey.
- ¹⁸⁰Hacettepe University, School of Medicine, Department of Chest Diseases, Immunology and Allergy Division, Ankara, Turkey.
- ¹⁸¹Allergy Centre, Tampere University Hospital, Tampere, Finland.
- ¹⁸²First Department of Family Medicine, Medical University of Lodz, Poland.
- ¹⁸³Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, and Institute of Health Resort Medicine and Health Promotion, Bavarian Health and Food Safety Authority, Bad Kissingen, Germany
- ¹⁸⁴Department of Medicine, McMaster University, Health Sciences Centre 3V47, West, Hamilton, Ontario, Canada.
- ¹⁸⁵National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation.
- ¹⁸⁶GARD Chairman, Geneva, Switzerland.
- ¹⁸⁷Allergy & Asthma Center Westend, Berlin, Germany.
- ¹⁸⁸Center for Rhinology and Allergology, Wiesbaden, Germany.
- ¹⁸⁹Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland.
- ¹⁹⁰Children's Hospital and University of Helsinki, Finland.
- ¹⁹¹Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm and Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden.
- ¹⁹²Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- ¹⁹³Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland.
- ¹⁹⁴Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.
- ¹⁹⁵Presidente CMMC, Milano, Italy.
- ¹⁹⁶Head of the Allergy Department of Pedro de Elizalde Children's Hospital, Buenos Aires, Argentina.
- ¹⁹⁷University of Medicine and Pharmacy, Hochiminh City, Vietnam.

- ¹⁹⁸Federal University of Bahia, Brazil.
- ¹⁹⁹Sifmed, Milano, Italy.
- ²⁰⁰State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- ²⁰¹Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, USA.
- ²⁰²Scottish Centre for Respiratory Research, Cardiovascular & Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, UK.
- ²⁰³Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.
- ²⁰⁴Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 research group, Liege, Belgium.
- ²⁰⁵Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
- ²⁰⁶Department of Philosophical, Methodological and Instrumental Disciplines, CUCS, University of Guadalajara, Guadalajara, Mexico.
- ²⁰⁷Department of Pulmonary Medicine, Rashid Hospital, Dubai, UAE.
- ²⁰⁸Biomax Informatics AG, Munich, Germany.
- ²⁰⁹Director General for Health and Social Care, Scottish Government, Edinburgh, UK.
- ²¹⁰Department of Respiratory Medicine, University of Bratislava, Bratislava, Slovakia.
- ²¹¹Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Portugal; Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal.
- ²¹²Medical center Iskar Ltd Sofia, Bulgaria.
- ²¹³Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland.
- ²¹⁴Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bizkaia, Spain
- ²¹⁵Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, Mississippi, USA.
- ²¹⁶Tobacco Control Research Centre;Iranian Anti Tobacco Association, Tehran, Iran.
- ²¹⁷Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina.
- ²¹⁸Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Mexico City, Mexico
- ²¹⁹University of Southeast Bahia, Brazil.
- ²²⁰Allergie-Centrum-Charité at the Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany
- ²²¹Maputo Central Hospital, Department of Paediatrics, Maputo, Mozambique.
- ²²²Allergologo, Veracruz, Mexico
- ²²³Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- ²²⁴Allergy and Asthma Medical Group and Research Center, San Diego, California, USA.
- ²²⁵CIRFF, Federico II University, Naples, Italy.
- ²²⁶Department of Physiology, CHRU, University Montpellier, Vice President for Research, PhyMedExp, INSERM U1046, CNRS UMR 9214, France.
- ²²⁷Croatian Pulmonary Society, Croatia.
- ²²⁸National Institute of Pneumology M Nasta, Bucharest, Romania.
- ²²⁹Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia.
- ²³⁰Regione Piemonte, Torino, Italy.
- ²³¹Col Jardines de Sta Monica, Tlalneptla, Mexico.
- ²³²National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, and Syrian Private University-Damascus, Syria.
- ²³³Department of Public health and health products, Paris Descartes University-Sorbonne Paris Cité, HERA Team, Inserm 1153 and Paris Municipal Department of social action, childhood, and health, Paris, France.
- ²³⁴Paris municipal Department of social action, childhood, and health, Paris, France.
- ²³⁵Lead Respiratory Physician Mater Dei Hospital Malta, Academic Head of Dept and Professor of Medicine University of Malta, Deputy Dean Faculty of Medicine and Surgery University of Medicine, La Valette, Malta.
- ²³⁶Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Maurizioano Hospital, Torino, Italy.
- ²³⁷Instituto de Prevision Social IPS HC, Socia de la SPAAI, Tesorera de la SLAAI, Asuncion, Paraguay.
- ²³⁸Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.
- ²³⁹Universidade de São Paulo, São Paulo, Brazil.
- ²⁴⁰Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Germany and CRI-Clinical Research International-Ltd, Hamburg, Germany.
- ²⁴¹General Pathology Institute, Faculty of Medicine, University of Coimbra, Portugal; Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal.
- ²⁴²Federal University of Bahia, Brazil.
- ²⁴³Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic; Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain.
- ²⁴⁴Danish Committee for Health Education, Copenhagen East, Denmark.
- ²⁴⁵Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy.
- ²⁴⁶Research Fellow, OPC, Cambridge, UK and Director, Medscript, Paraparaumu, New Zealand.
- ²⁴⁷Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- ²⁴⁸General Manager of COFASER - Pharmacy Services Consortium, Salerno, Italy.

- ²⁴⁹Scientific Centre of Children's Health under the MoH, Moscow, Russian National Research Medical University named Pirogov, Moscow, Russia.
- ²⁵⁰Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina Center for Allergy and Immunology, Santa Fe, Argentina.
- ²⁵¹Dept of Otorhinolaryngology, Medical University of Vienna, AKH, Vienna, Austria.
- ²⁵²Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.
- ²⁵³Die Hautambulanz and Rothhaar study center, Berlin, Germany.
- ²⁵⁴Neumología y Alergología Infantil, Hospital La Fe, Valencia, Spain.
- ²⁵⁵Center for Health Technology and Services Research - CINTESIS and Department of Internal Medicine, Centro Hospitalar Sao Joao, Porto, Portugal.
- ²⁵⁶Caisse d'assurance retraite et de la santé au travail du Languedoc-Roussillon (CARSAT-LR), Montpellier, France.
- ²⁵⁷Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy.
- ²⁵⁸ENT Department, University Hospital of Kinshasa, Kinshasa, Congo.
- ²⁵⁹Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Immunology, Monash University, Melbourne, Victoria, Australia.
- ²⁶⁰Medical center "Research expert", Varna, Bulgaria.
- ²⁶¹National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.
- ²⁶²Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.
- ²⁶³Dept of Otolaryngology, Nippon Medical School, Tokyo, Japan.
- ²⁶⁴Allergologo, Jalisco, Guadalajara, Mexico.
- ²⁶⁵Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso.
- ²⁶⁶Dept of Comparative Medicine; Messerli Research Institute of the University of Veterinary Medicine and Medical University, Vienna, Austria.
- ²⁶⁷Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- ²⁶⁸Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK, and Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou," University of Athens, Athens, Greece.
- ²⁶⁹Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.
- ²⁷⁰Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
- ²⁷¹Allergy and Respiratory Diseases, Ospedale Policlinico San Martino -University of Genoa, Italy.
- ²⁷²Farmacias Holon, Lisbon, Portugal.
- ²⁷³Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
- ²⁷⁴University of Southern Denmark, Kolding, Denmark.
- ²⁷⁵Université Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, France.
- ²⁷⁶Allergy Unit, CUF-Porto Hospital and Institute; Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Portugal.
- ²⁷⁷Sociologist, municipality area n33, Sorrento, Italy.
- ²⁷⁸Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Germany
- ²⁷⁹Division of Respiratory and Allergic Diseases, Hospital 'A Cardarelli', University of Naples Federico II, Naples, Italy.
- ²⁸⁰Centre for empowering people and communities, Dublin, UK.
- ²⁸¹Conseil Général de l'Economie Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France.
- ²⁸²Société de Pneumologie de Langue Française, Espace francophone de Pneumologie, Paris, France.
- ²⁸³Département de pédiatrie, CHU de Grenoble, Grenoble, France.
- ²⁸⁴Medical School, University of Cyprus, Nicosia, Cyprus.
- ²⁸⁵Children's Hospital Srebrnjak, Zagreb, School of Medicine, University JJ Strossmayer, Osijek, Croatia.
- ²⁸⁶Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria.
- ²⁸⁷University Hospital 'Sv. Ivan Rilski', Sofia, Bulgaria.
- ²⁸⁸Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa.
- ²⁸⁹Vice-Presidente of IML, Milano, Italy.
- ²⁹⁰Observational and Pragmatic Research Institute, Singapore, Singapore.
- ²⁹¹Department of Otorhinolaryngology University of Crete School of Medicine, Heraklion, Greece.
- ²⁹²European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium.
- ²⁹³Allergologo, Cancun Quintana Roo, Mexico.
- ²⁹⁴LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany Department of Medicine, Christian Albrechts University, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany.
- ²⁹⁵Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden.
- ²⁹⁶Farmácia São Paio, Vila Nova de Gaia, Porto, Portugal.
- ²⁹⁷St Vincent's Hospital and University of Sydney, Sydney, New South Wales, Australia.
- ²⁹⁸Allergologo, Mexico City, Mexico
- ²⁹⁹Serviço de Pneumologia-Hosp das Clinicas UFPE-EBSERH, Recife, Brazil.
- ³⁰⁰Universidade Federal de São Paulo, São Paulo, Brazil.
- ³⁰¹Centre of Pneumology, Coimbra University Hospital, Portugal.
- ³⁰²Polibienestar Research Institute, University of Valencia, Valencia, Spain.

- ³⁰³Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico City, Mexico.
- ³⁰⁴Getafe University Hospital Department of Geriatrics, Madrid, Spain.
- ³⁰⁵Association Asthme et Allergie, Paris, France.
- ³⁰⁶Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- ³⁰⁷Primary Care Respiratory Research Unit Institutode Investigación Sanitaria de Palma IdisPa, Palma de Mallorca, Spain.
- ³⁰⁸Allergy Unit, Presidio Columbus, Rome, Catholic University of Sacred Heart, Rome and IRCCS Oasi Maria SS, Troina, Italy.
- ³⁰⁹Hospital General, Mexico City, Mexico.
- ³¹⁰Regione Piemonte, Torino, Italy.
- ³¹¹Medical University of Graz, Department of Internal Medicine, Graz, Austria.
- ³¹²Serviço de Imunoalergologia Hospital da Luz, Lisboa, Portugal.
- ³¹³Hospital de Clinicas, University of Parana, Brazil.
- ³¹⁴Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel.
- ³¹⁵Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK.
- ³¹⁶Showa University School of Medicine, Tokyo, Japan.
- ³¹⁷Association of Finnish Pharmacies, Helsinki, Finland.
- ³¹⁸Allergy and Clinical Immunology Department, Centro Médico- Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela.
- ³¹⁹Faculty of Medicine, Autononous University of Madrid, Spain.
- ³²⁰The Royal National TNE Hospital, University College London, UK.
- ³²¹DIBIMIS, University of Palermo, Italy.
- ³²²Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland.
- ³²³Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericórdia de Vitoria - Esperito Santo, Brazil.
- ³²⁴The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
- ³²⁵Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
- ³²⁶INSERM, Université Grenoble Alpes, IAB, U 1209, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Université Joseph Fourier, Grenoble, France.
- ³²⁷Sociedad Paraguaya de Alergia Asma e Inmunologia, Paraguay.
- ³²⁸Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
- ³²⁹European Health Futures Forum (EHFF), Dromahair, Ireland.
- ³³⁰ENT, Aachen, Germany.
- ³³¹Kyrgyzstan National Centre of Cardiology and Internal medicine, Euro-Asian respiratory Society, Bishkek, Kyrgyzstan.
- ³³²University Hospital Olomouc, Czech Republic.
- ³³³Department of Paediatric and Adolescent medicine, University Hospital of North Norway, Tromsø, Paediatric Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
- ³³⁴Presidente, IML (Lombardy Medical Initiative), Bergamo, Italy.
- ³³⁵Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
- ³³⁶Public Health Institute of Vilnius University, Vilnius, Lithuania.
- ³³⁷Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
- ³³⁸RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France.
- ³³⁹The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Canada.
- ³⁴⁰Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Portugal.
- ³⁴¹Department of General ORL, H&NS, Medical University of Graz, ENT University Hospital, Graz, Austria.
- ³⁴²Campania Region, Division on Pharmacy and devices policy, Naples, Italy.
- ³⁴³Department of Respiratory Medicine, Hvidovre Hospital & University of Copenhagen, Denmark.
- ³⁴⁴Universidade Federal dos Pampas, Uruguaiiana, Brazil.
- ³⁴⁵Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, and Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.
- ³⁴⁶Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Spain.
- ³⁴⁷Vilnius University Medical Faculty Institute of Clinical Medicine and Institute of Health Sciences, Vilnius, Lithuania.
- ³⁴⁸Department of Lung Diseases and Clinical Immunology Allergology, University of Turku and Terveystalo allergy clinic, Turku, Finland.
- ³⁴⁹PELyon; HESPER 7425, Health Services and Performance Resarch - Université Claude Bernard Lyon, France.
- ³⁵⁰Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm, Sweden.
- ³⁵¹Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
- ³⁵²University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.
- ³⁵³Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Italy.
- ³⁵⁴FILHA, Finnish Lung Association, Helsinki, Finland.
- ³⁵⁵Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy; and CNR Institute of Biomedicine and Molecular Immunology "A Monroy", Palermo, Italy.
- ³⁵⁶Medical University, Department of Otorhinolaryngology, Plovdiv, Bulgaria.

³⁵⁷Sotiria Hospital, Athens, Greece.

³⁵⁸Dept of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Germany.

³⁵⁹Asthma UK, Mansell street, London, UK.

³⁶⁰Nova Southeastern University, Fort Lauderdale, Florida, USA.

³⁶¹Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

³⁶²Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.

³⁶³Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.

³⁶⁴Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Department of ENT diseases, Karolinska University Hospital, Stockholm, Sweden.

³⁶⁵Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

³⁶⁶International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.

³⁶⁷Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, UK.

³⁶⁸Allergologist - Medical College of Medical Faculty, Thracian University, Stara Zagora, Bulgaria.

³⁶⁹Department of Research, Olmsted Medical Center, Rochester, Minnesota, USA.

³⁷⁰Cyprus International Institute for Environmental & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus; Department of Pediatrics, Hospital "Archbishop Makarios III", Nicosia, Cyprus.

³⁷¹Celal Bayar University Department of Pulmonology, Manisa, Turkey.

³⁷²The Allergy and Asthma Institute, Islamabad, Pakistan.

³⁷³Department of Paediatrics and Child Health, Red Cross Children's

Hospital, and MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa.

³⁷⁴Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China.

³⁷⁵Universidad Católica de Córdoba, Córdoba, Argentina.

³⁷⁶University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.

³⁷⁷Gesundheitsregion KölnBonn - HRCB Projekt GmbH, Kohn, Germany.

³⁷⁸Akershus University Hospital, Department of Otorhinolaryngology, Akershus, Norway.

³⁷⁹Chief of Staff, the Northern Health Science Alliance (NHSA) and Director and Founder of Northern Health Matters Ltd, Manchester, UK.

³⁸⁰President of Kazakhstan Association of Allergology and Clinical Immunology, Department of Allergology and Clinical Immunology of the Kazakh National Medical University, Kazakhstan.

³⁸¹ICREA and Climate and Health (CLIMA) Program, ISGlobal, Barcelona, Spain

³⁸²Department of Otorhinolaryngology, Head and Neck Surgery, Ankara, Turkey and Department of Otorhinolaryngology, Head and Neck Surgery, Salzburg Paracelsus Medical University, Austria

³⁸³President of European Rhinologic Society, 1st Dept of ORL, Head & Neck Surgery, Aristotle University, Thessaloniki, Greece and Professor of FAU Erlangen-Nurnberg University, Germany

³⁸⁴ThermoFisher Scientific, Uppsala, Sweden

³⁸⁵Institute of Health Resort Medicine and Health Promotion, Bavarian Health and Food Safety Authority, Bad Kissingen, Germany.